Height, selected genetic markers and prostate cancer risk: results from the PRACTICAL consortium.

Thumbnail Image

Files

bjc2017231a.pdf (457.27 KB)
28765617+Supplement+tables_MODIFIED+Height.pdf (677.23 KB)

Embargo End Date

ICR Authors

Kote-Jarai, Zsofia
 Eeles, Rosalind

Authors

Lophatananon, A
Stewart-Brown, S
Kote-Jarai, Z
Olama, AAA
Garcia, SB
Neal, DE
Hamdy, FC
Donovan, JL
Giles, GG
Fitzgerald, LM
Southey, MC
Pharoah, P
Pashayan, N
Gronberg, H
Wiklund, F
Aly, M
Stanford, JL
Brenner, H
Dieffenbach, AK
Arndt, V
Park, JY
Lin, H-Y
Sellers, T
Slavov, C
Kaneva, R
Mitev, V
Batra, J
Spurdle, A
Clements, JA
APCB BioResource,
PRACTICAL consortium,
Easton, D
Eeles, RA
Muir, K

Document Type

Journal Article

Date

2017-08-22

Date Accepted

2017-06-23

Abstract

BACKGROUND: Evidence on height and prostate cancer risk is mixed, however, recent studies with large data sets support a possible role for its association with the risk of aggressive prostate cancer. METHODS: We analysed data from the PRACTICAL consortium consisting of 6207 prostate cancer cases and 6016 controls and a subset of high grade cases (2480 cases). We explored height, polymorphisms in genes related to growth processes as main effects and their possible interactions. RESULTS: The results suggest that height is associated with high-grade prostate cancer risk. Men with height >180 cm are at a 22% increased risk as compared to men with height <173 cm (OR 1.22, 95% CI 1.01-1.48). Genetic variants in the growth pathway gene showed an association with prostate cancer risk. The aggregate scores of the selected variants identified a significantly increased risk of overall prostate cancer and high-grade prostate cancer by 13% and 15%, respectively, in the highest score group as compared to lowest score group. CONCLUSIONS: There was no evidence of gene-environment interaction between height and the selected candidate SNPs.Our findings suggest a role of height in high-grade prostate cancer. The effect of genetic variants in the genes related to growth is seen in all cases and high-grade prostate cancer. There is no interaction between these two exposures.

Citation

British journal of cancer, 2017, 117 (5), pp. 734 - 743

DOI

10.1038/bjc.2017.231

URI

https://repository.icr.ac.uk/handle/internal/894

Rights

https://creativecommons.org/licenses/by/4.0

Source Title

Publisher

NATURE PUBLISHING GROUP

ISSN

0007-0920

eISSN

1532-1827

Collections

Genetics and Epidemiology
Radiotherapy and Imaging

Research Team

Oncogenetics

Notes